Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAK | O14976 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769608 | 0.90 | PRKDC (0.40) | PRKDCNPC1RAB9ACHRNA7ALDH1A1 | |
| SCHEMBL3759018 | 0.89 | ROCK1 (0.40) | PRKDCNPC1RAB9AALDH1A1GAK | |
| SCHEMBL3751898 | 0.88 | NPC1 (0.46) | PRKDCNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL3763755 | 0.86 | ALDH1A1 (0.34) | KMT2ACHRNA7ALDH1A1LMNA | |
| SCHEMBL16161666 | 0.86 | POLB (0.42) | PRKDCNPC1RAB9AKMT2ACHRNA7 | |
| SCHEMBL3757637 | 0.85 | KDM4E (0.48) | PRKDCNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL3766528 | 0.84 | PRKDC (0.52) | PRKDCNPC1RAB9AKMT2ACHRNA7 | |
| SCHEMBL3751903 | 0.84 | NPC1 (0.41) | PRKDCNPC1RAB9AALDH1A1GAK | |
| SCHEMBL16161821 | 0.84 | GAA (0.46) | PRKDCNPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL3760240 | 0.84 | PTPN1 (0.44) | PRKDCKMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | PRKDC 112/4885NPC1 3855/4885RAB9A 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.